Research Topic

New Drug Options for Prevention and Therapy of Cardiovascular Diseases

About this Research Topic

Prevention of cardiovascular diseases including coronary heart disease and heart failure via treatment of cardiovascular risk factors has contributed to the increase in life expectancy. In addition, understanding the pathophysiological background of the diseases and the changes in cardiovascular function with age, like vascular stiffening that act as significant co-morbidities has paved the way for the development of new therapeutic options. The increase in availability of therapeutic options for certain diseases as well as new methods to target specific organs has enabled the development of custom-made individualized therapies.

In recent years the significance of certain cardiovascular risk factors like hyperlipidaemia and arterial hypertension has been elucidated. Understanding the pathophysiology behind these conditions has led to the discovery of new therapeutic targets including antibodies against proprotein convertase subtilisin/kexin type 9 (PSCK9) and siRNA. Targeting organ specific receptors as the asialoglycoprotein receptor in case of the PCSK9 siRNA inclisiran has allowed to reduce the amount of side effects.
While previous therapeutic options targeting brain natriuretic peptide (BNP) failed, angiotensin-receptor/neprilysin-inhibitors have quickly emerged to become a standard medication for heart failure therapy. Sodium-glucose linked transporter 2 (SGLT-2) inhibitors were first developed to treat patients with diabetes, one of the greatest risk factors for the development of cardiovascular diseases and has become a new cornerstone in heart failure therapy. At the same time more research is needed to identify new targets in order to further individualize cardiovascular prevention and therapy.

This Research Topic invites submissions regarding the drug therapy of cardiovascular risk factors like hyperlipidaemia, hypertension, and diabetes, the resulting endothelial dysfunction and associated vascular inflammation and platelet hyperactivity, as well as those concerning modern treatment options for coronary heart disease and heart failure. There shall be a special focus on innovative, organ targeting medications aiming to reduce the burden of side effects. Likewise, work on individualized drug therapy will be highly appreciated with a special focus on the needs of the elderly. In addition to single target strategies, we specifically encourage submissions of manuscripts addressing multi-target strategies for therapy. Original research as well as review articles are welcome, which will address the topics on a molecular, biochemical and/or clinical aspect using cell-culture and or animal models, omics techniques, imaging approaches and/or clinical research.

Topic Editor Stephanie Könemann has received speaker fees from Novartis and Daiichi Sankyo


Keywords: Cardiovascular diseases, Cardiovascular risk factors, Pharmacotherapy, Regenerative therapies, Vascular biology


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Prevention of cardiovascular diseases including coronary heart disease and heart failure via treatment of cardiovascular risk factors has contributed to the increase in life expectancy. In addition, understanding the pathophysiological background of the diseases and the changes in cardiovascular function with age, like vascular stiffening that act as significant co-morbidities has paved the way for the development of new therapeutic options. The increase in availability of therapeutic options for certain diseases as well as new methods to target specific organs has enabled the development of custom-made individualized therapies.

In recent years the significance of certain cardiovascular risk factors like hyperlipidaemia and arterial hypertension has been elucidated. Understanding the pathophysiology behind these conditions has led to the discovery of new therapeutic targets including antibodies against proprotein convertase subtilisin/kexin type 9 (PSCK9) and siRNA. Targeting organ specific receptors as the asialoglycoprotein receptor in case of the PCSK9 siRNA inclisiran has allowed to reduce the amount of side effects.
While previous therapeutic options targeting brain natriuretic peptide (BNP) failed, angiotensin-receptor/neprilysin-inhibitors have quickly emerged to become a standard medication for heart failure therapy. Sodium-glucose linked transporter 2 (SGLT-2) inhibitors were first developed to treat patients with diabetes, one of the greatest risk factors for the development of cardiovascular diseases and has become a new cornerstone in heart failure therapy. At the same time more research is needed to identify new targets in order to further individualize cardiovascular prevention and therapy.

This Research Topic invites submissions regarding the drug therapy of cardiovascular risk factors like hyperlipidaemia, hypertension, and diabetes, the resulting endothelial dysfunction and associated vascular inflammation and platelet hyperactivity, as well as those concerning modern treatment options for coronary heart disease and heart failure. There shall be a special focus on innovative, organ targeting medications aiming to reduce the burden of side effects. Likewise, work on individualized drug therapy will be highly appreciated with a special focus on the needs of the elderly. In addition to single target strategies, we specifically encourage submissions of manuscripts addressing multi-target strategies for therapy. Original research as well as review articles are welcome, which will address the topics on a molecular, biochemical and/or clinical aspect using cell-culture and or animal models, omics techniques, imaging approaches and/or clinical research.

Topic Editor Stephanie Könemann has received speaker fees from Novartis and Daiichi Sankyo


Keywords: Cardiovascular diseases, Cardiovascular risk factors, Pharmacotherapy, Regenerative therapies, Vascular biology


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

11 September 2021 Abstract
10 January 2022 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

11 September 2021 Abstract
10 January 2022 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..